1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. [electronic resource]
Producer: 20061218Description: 2499-503 p. digitalISSN:- 0959-8049
- Antineoplastic Agents, Alkylating -- therapeutic use
- Brain Neoplasms -- drug therapy
- Chromosomes, Human, Pair 1
- Chromosomes, Human, Pair 19
- Clinical Trials, Phase II as Topic
- Dacarbazine -- analogs & derivatives
- Disease-Free Survival
- Humans
- In Situ Hybridization, Fluorescence
- Multicenter Studies as Topic
- Neoplasm Recurrence, Local -- drug therapy
- Oligodendroglioma -- drug therapy
- Prospective Studies
- Salvage Therapy
- Survival Analysis
- Temozolomide
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.